The Informed Consent Gap: Emergency Use Authorization and the Mandate Contradiction

On July 6, 2021, the Department of Justice Office of Legal Counsel issued an opinion that would structure the legal architecture of America's pandemic response for the next eighteen months. The question was narrow: does Section 564 of the Federal Food, Drug, and Cosmetic Act — the statute governing Emergency Use Authorization — prohibit employers from requiring COVID-19 vaccination? The DOJ's answer was no. The statute, the DOJ concluded, requires only that recipients be informed of the option to refuse. It does not prohibit other parties from imposing consequences for exercising that option.

That opinion converted informed consent from a substantive right into a procedural formality. You must be told you can say no. You may then lose your job, your airline access, your military career, your university enrollment, and your ability to participate in large segments of public life for saying no. But you were informed.

This article does not argue whether the COVID-19 vaccines were safe or effective. Many were both. It argues something narrower and more durable: that the legal architecture of Emergency Use Authorization and the legal architecture of vaccine mandates are structurally incompatible, and that operating both simultaneously — on the same product, for the same population, during the same emergency — generated a contradiction that undermined informed consent, eroded institutional trust, and established precedents that will shape every future public health emergency.

The Statute: What EUA Actually Requires

Section 564 of the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. § 360bbb-3, establishes the legal framework for Emergency Use Authorization. The statute permits the FDA to authorize products — drugs, devices, biological products — for use during declared emergencies, even when those products have not completed the standard approval process.

The statute imposes conditions. Among them, the FDA must ensure — "to the extent practicable" given emergency circumstances — that individuals receiving an EUA product are informed of three things:

Read that third requirement carefully. The statute does not merely permit refusal. It mandates disclosure of the option to refuse, the consequences of refusing, and the alternatives available. This is the architecture of informed consent — not informed compliance. The entire structure of the disclosure assumes a decision-making agent who will weigh benefits, risks, unknowns, consequences, and alternatives before making a choice.

The statute also requires disclosure that the benefits and risks are partially unknown — an acknowledgment, encoded in law, that the product's safety and efficacy profile is incomplete. This is not a deficiency. It is the defining characteristic of an EUA product: it has been authorized on the basis of available evidence during an emergency, not on the basis of the complete evidence required for standard approval. The regulatory classification itself communicates: we believe this is likely safe and effective, but we don't yet have the full data.

The DOJ Reinterpretation: Inform, Then Override

The DOJ's July 2021 opinion addressed the tension between the EUA statute's "option to refuse" language and employer vaccination mandates. The opinion's core reasoning proceeded in two steps.

Step one: The word "informed" means what it commonly means — to tell someone something. The statute requires that recipients be told they have the option to refuse. It requires disclosure, not protection of the option itself.

Step two: The statute imposes obligations on the parties administering the EUA product (principally the FDA and vaccine providers). It does not impose obligations on employers, universities, or other third parties. Therefore, those third parties remain free to impose vaccination requirements with whatever consequences they choose — including termination — without violating the EUA statute.

The DOJ went further, noting that the statute allows the FDA to inform recipients of "the consequences, if any, of refusing administration." Under the DOJ's reading, job loss, economic exclusion, and restricted social participation are simply among the consequences a recipient might be informed about — not consequences the statute prohibits.

As a matter of statutory interpretation, the DOJ's reading is defensible. The text does say "informed." It does not say "protected." The statute's obligations do run to the administering parties, not to employers. But statutory interpretation and structural coherence are different questions. The fact that a reading is textually supportable does not mean it produces a legally coherent architecture. And the architecture produced by the DOJ's reading is a system at war with itself.

The Structural Contradiction

Consider what the combined architecture — EUA disclosure plus mandate enforcement — communicates to a recipient:

The contradiction is not merely rhetorical. It is structural. The EUA framework was designed to operate in a consent-based environment. Its disclosure requirements assume a recipient who will process information and make a voluntary choice. The mandate framework operates in a compliance-based environment. Its enforcement mechanisms assume a recipient who will comply under penalty. These two frameworks produce opposite incentive structures, opposite communication logics, and opposite trust signals — and they were applied to the same product, for the same population, at the same time.

The result was predictable: neither framework achieved its intended purpose. The EUA's informed consent disclosures were rendered hollow by the mandate — because a "choice" between accepting an incompletely-tested product and losing your income is not a choice the informed consent tradition recognizes as voluntary. And the mandate's compliance function was undermined by the EUA disclosures — because every fact sheet handed to a vaccine recipient reminded them, by statute, that the product's risks were partially unknown and that they had the option to refuse.

The Informed Consent Tradition

Informed consent is not a bureaucratic formality. It is the foundational ethical achievement of modern medicine — earned through catastrophic violations that demonstrated why it matters.

The Nuremberg Code (1947) established that voluntary consent is "absolutely essential" for any medical procedure and that the person must be "able to exercise free power of choice, without the intervention of any element of force, fraud, deceit, duress, overreaching, or other ulterior form of constraint or coercion." The Belmont Report (1979) — a foundational document in Professor Buck's own syllabus at the University of Tennessee — codified the principles of respect for persons, beneficence, and justice, with informed consent as the operational expression of respect for persons.

The common thread across the entire informed consent tradition is this: consent given under economic duress is not voluntary consent. A prisoner who "consents" to an experiment in exchange for privileges has not given informed consent. A patient who "consents" to a procedure because the alternative is being denied care has not given informed consent. And an employee who "consents" to an EUA product because the alternative is termination has not given informed consent in any sense the Nuremberg Code, the Belmont Report, or the common-law tradition would recognize.

The DOJ opinion acknowledged that the EUA statute requires informing recipients of the option to refuse. But it defined "inform" as a speech act, not a structural protection. Under this reading, you can inform someone of a right while simultaneously eliminating its practical exercise. The recipient knows they can refuse. They also know that refusal costs them their income. The DOJ opinion treats this as informed consent. The Nuremberg Code, the Belmont Report, and the common-law tradition treat it as coercion wearing the costume of disclosure.

The Military Precedent: Where Waiver Requires Presidential Action

Congress itself recognized the tension between EUA products and mandatory administration — in one specific context. Under 10 U.S.C. § 1107a, when the military administers an EUA product to armed forces members, the "option to accept or refuse" condition can be waived — but only by the President, only in writing, and only upon a determination that compliance is necessary for national security.

This provision is structurally revealing. Congress understood that mandating an EUA product is in tension with the informed consent protections built into the EUA framework. For the military context, Congress created a specific, narrow exception — requiring the highest possible authority, a written determination, and a national security justification. The very existence of this exception implies that, absent presidential waiver, the informed consent protections are substantive, not merely procedural.

For the civilian population, no comparable waiver mechanism exists. Congress never created one — which means either Congress intended civilian informed consent to be inviolable under EUA conditions, or Congress never anticipated that civilian employers would impose mandates for EUA products. Either reading leads to the same conclusion: the mandate-under-EUA architecture was never designed to work. It was improvised under emergency pressure, legally rationalized after the fact, and structurally incoherent from the beginning.

The BLA Timeline: When Approval Changed Nothing

On August 23, 2021, the FDA granted full Biologics License Application (BLA) approval to the Pfizer-BioNTech vaccine under the brand name Comirnaty. This approval was immediately cited as resolving the EUA-mandate contradiction: the product was now fully approved, so EUA consent protections no longer applied.

But the resolution was incomplete. For months after the BLA approval, the vaccine administered at most sites was the EUA-authorized version — legally distinct from the BLA-approved product, though biologically identical. The BLA-approved Comirnaty was not widely available. Mandates citing "FDA-approved" vaccines were, in practice, requiring EUA products — under the authority of an approval that applied to a product most recipients could not actually obtain.

More fundamentally, the BLA approval did not retroactively resolve the consent violation that occurred during the months when mandates applied to EUA products exclusively. Between the initiation of employer mandates in summer 2021 and the BLA approval in August, millions of Americans were required — under penalty of employment loss — to accept a product whose own regulatory classification acknowledged incomplete safety data and whose authorizing statute preserved the option to refuse. That period produced real consequences for real people, and the subsequent approval does not erase the structural incoherence of the mandate-under-EUA architecture during the months it operated.

The Anthrax Precedent: What History Already Taught

This was not the first time an EUA product met a mandate. The 2005 Federal Register, establishing the framework for the first-ever EUA (anthrax vaccine for military personnel), explicitly addressed the consent question. The precedent established that EUA products carried a right of refusal — and that the military context required the presidential waiver process precisely because mandatory administration of an EUA product was understood to be an exception requiring extraordinary authority.

The COVID-19 civilian mandate bypassed this entire precedential architecture. No equivalent authority was invoked. No comparable waiver process was created. The DOJ opinion reinterpreted the statute's plain language to permit what the anthrax precedent had required presidential action to authorize. Whether that reinterpretation was legally correct is a question courts are still adjudicating. Whether it was structurally coherent with the informed consent tradition is a question the data has already answered: it was not.

The Downstream Effect: Consent as Eroded Infrastructure

The most consequential damage from the EUA-mandate contradiction is not legal. It is cultural. The informed consent tradition depends on a shared understanding between institutions and populations: your decision about your body is yours. When that understanding is violated — even once, even with good intentions, even during an emergency — the violation creates a precedent in the population's institutional memory.

That precedent now operates. Every future public health recommendation — however well-supported, however rigorously tested, however different from the COVID-19 context — will be received by a segment of the population through the filter of the 2021 experience: last time, they told us we had a choice, and then they took the choice away. The informed consent tradition was not just violated as a legal matter. It was violated as a social contract. And social contracts, once broken, are rebuilt over decades, not news cycles.

The childhood vaccination decline — from 95% to 92.5% for MMR, with exemptions at record 3.6% — is one measure of this erosion. Parents who previously accepted routine vaccinations without question now question them — not because the science on MMR has changed, but because the trust architecture within which vaccination recommendations are received has been damaged. The EUA-mandate contradiction communicated a meta-message that no subsequent reassurance can easily undo: when institutions say you have a choice, they may not mean it.

Structural Principles for the Next Emergency

The next novel pathogen will not wait for the informed consent tradition to rebuild itself. When it arrives, regulators will again face the question: can we mandate an EUA product? The COVID-19 experiment suggests three structural principles:

First, EUA and mandates are architecturally incompatible. A regulatory pathway that acknowledges incomplete data and preserves refusal rights cannot coexist with an enforcement mechanism that eliminates refusal's practical meaning. Future emergency responses must choose one architecture or the other. They cannot occupy both simultaneously without generating contradictions that undermine both.

Second, informed consent is infrastructure, not formality. Reducing "informed of the option to refuse" to a procedural speech act — tell them they can say no, then punish them for saying no — is not informed consent. It is the form of consent emptied of its substance. Populations can detect the difference, and when they do, the institutional credibility required for voluntary cooperation collapses.

Third, emergency authority requires explicit expiration. The EUA framework was designed as temporary. When mandates extended that temporary authority into a standing behavioral requirement — for employment, for education, for social participation — they converted an emergency mechanism into a governance structure. Emergency authority that cannot articulate its own endpoint is no longer emergency authority. It is expansion.

The application is structural. An informed consent architecture that says "yes, you may refuse" while a mandate architecture simultaneously says "no, you may not refuse without consequence" is neither yes nor no. It is both — and the population, correctly, trusts neither.

The Bottom Line

The Emergency Use Authorization framework and vaccine mandates are two legal architectures built on incompatible foundations. One communicates: this product is provisionally authorized, its risks are partially unknown, and you have the right to refuse it. The other communicates: take this product or lose your livelihood. The DOJ reconciled these by redefining informed consent as a disclosure requirement rather than a protection of voluntary choice. That reinterpretation was textually defensible and structurally incoherent.

The structural incoherence produced precisely the outcome that the informed consent tradition exists to prevent: a population that can no longer distinguish between genuine choice and coerced compliance, between substantive consent and procedural theater. That population now extends its distrust beyond COVID-19 vaccines to routine childhood immunizations, to public health recommendations generally, and to the institutions that issued them.

This was not inevitable. A response architecture that preserved the EUA's consent protections — that treated the option to refuse as substantive rather than procedural — would have achieved lower short-term compliance numbers and higher long-term institutional trust. The mandate traded the latter for the former. The exchange rate, measured in childhood vaccination declines, measles outbreaks, and generational trust erosion, is proving catastrophic.

The notation matters. The pathway matters. The form-then-breath sequence matters. You do not get to the same place by collapsing the architecture — even if the arithmetic looks identical.